Investigating how hearing ourselves speak affects speech movements
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
This study is testing how hearing ourselves talk affects our speech movements in both regular speakers and patients with brain implants to see how it influences how we adjust our speech.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 507 (estimated) |
| Ages | 4 Years and up |
| Sex | All |
| Sponsor | University of Washington Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT06164717 on ClinicalTrials.gov |
What this trial studies
This study explores the relationship between auditory feedback and speech motor control in both typical speakers and patients with Deep Brain Stimulation (DBS) implants. Participants will read various speech tasks while their speech is recorded, and some will have their brain activity monitored with an electrode cap. The study aims to determine how self-perception of speech influences future speech movements and to identify brain areas involved in speech adjustment for DBS patients. The tasks will be conducted with the DBS stimulator both ON and OFF to assess its impact.
Who should consider this trial
Good fit: Ideal candidates include native American English speakers aged 4 years and older, with no significant communication or neurological issues, and DBS patients with specific electrode implants.
Not a fit: Patients with severe communication or neurological problems unrelated to DBS may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of speech motor control, potentially leading to improved therapies for individuals with speech disorders.
How similar studies have performed: While this study investigates a novel approach, similar studies have shown promise in understanding speech motor control and the effects of auditory feedback.
Eligibility criteria
Show full inclusion / exclusion criteria
General inclusion criteria: * native speaker of American English * no communication or neurological problems (except for subjects in the DBS group) * 250-4000 Hz pure tone hearing thresholds equal to or better than 25 dB HL for children and young adults and equal to or better than 35 dB HL for older adults * no medications that affect sensorimotor functioning (except for in the DBS group) * adult subjects: 18 years of age or older * typical children: 4;0 to 6;11 \[years;months\] or 10;0 to 12;11 \[years;months\]) Specific inclusion criteria for children: \* scoring above the 20th percentile on the Peabody Picture Vocabulary Test (PPVT-5), Expressive Vocabulary Test (EVT-3), Goldman-Fristoe Test of Articulation (GFTA-3), and either Test of Early Language Development (TELD-4) or (for children age 8 or older) Clinical Evaluation of Language Fundamentals (CELF-5). Specific inclusion criteria for DBS patients: \* bilateral electrodes implanted in either the ventral intermediate nucleus of the thalamus (Vim; a target site for patients with essential tremor) or subthalamic nucleus (STN; a target site for patients with Parkinson's disease)
Where this trial is running
Seattle, Washington
- University of Washington — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Ludo Max, Ph.D. — University of Washington
- Study coordinator: Ludo Max
- Email: ludomax@uw.edu
- Phone: 206-543-2674
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.